English
简体中文
Total: £ 56.28
Published Date: 2026-02-03 | Pages: 109 | Tables: 116 | Medical Care
The global circRNA-LNP Formulation market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on circRNA-LNP Formulation competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Circular RNAs (circRNAs) are covalently closed RNA molecules generated mainly from pre-mRNA back-splicing, and have also been found to function as mRNAs to direct protein synthesis inside cells. As a new generation of therapeutic mRNAs, circRNAs may address some of the limitations of linear mRNA including increased stability, reduced immunogenicity, and tissue/cell-specific translation. Therefore, translatable circRNAs are able to produce more therapeutic protein inside the body than conventional mRNA, with the potential to engineer cells, replace damaged proteins, or add new beneficial proteins for patients with serious diseases.LNPs have been proven to be an effective drug delivery system for RNA therapeutics which can be easily degraded in vivo. The lipid layer can fuse with the cell membrane, allowing the encapsulated RNA to enter the cell and exert its therapeutic effect. They also protect therapeutic agents from degradation and improve their bioavailability.
The North American market for circRNA-LNP Formulation is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for circRNA-LNP Formulation is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of circRNA-LNP Formulation include Orna Therapeutics, GenScript, Creative Biogene, Catalent, Creative Biolabs, VectorBuilder, Guangzhou Geneseed Biotech. Co., Ltd., Porton Pharma Solutions, Ltd, Recipharm AB, Precigenome LLC, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global circRNA-LNP Formulation market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding circRNA-LNP Formulation. The circRNA-LNP Formulation market size, estimates, and forecasts are provided in terms of sales volume (Kg) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global circRNA-LNP Formulation market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist circRNA-LNP Formulation manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Orna Therapeutics
GenScript
Creative Biogene
Catalent
Creative Biolabs
VectorBuilder
Guangzhou Geneseed Biotech. Co., Ltd.
Porton Pharma Solutions, Ltd
Recipharm AB
Precigenome LLC
Segment by Type
Premade
Customized
by Application
Scientific Research
Pharmaceuticals
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for circRNA-LNP Formulation manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines circRNA-LNP Formulation sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 circRNA-LNP Formulation Market Overview
1.1 Product Definition
1.2 circRNA-LNP Formulation by Type
1.2.1 Global circRNA-LNP Formulation Market Value by Type: 2025 vs 2032
1.2.2 Premade
1.2.3 Customized
1.3 circRNA-LNP Formulation by Application
1.3.1 Global circRNA-LNP Formulation Market Value by Application: 2025 vs 2032
1.3.2 Scientific Research
1.3.3 Pharmaceuticals
1.4 Global circRNA-LNP Formulation Market Size Estimates and Forecasts
1.4.1 Global circRNA-LNP Formulation Revenue 2021–2032
1.4.2 Global circRNA-LNP Formulation Sales 2021–2032
1.4.3 Global circRNA-LNP Formulation Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 circRNA-LNP Formulation Market Competition by Manufacturers
2.1 Global circRNA-LNP Formulation Sales Market Share by Manufacturers (2021–2026)
2.2 Global circRNA-LNP Formulation Revenue Market Share by Manufacturers (2021–2026)
2.3 Global circRNA-LNP Formulation Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of circRNA-LNP Formulation, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of circRNA-LNP Formulation, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of circRNA-LNP Formulation, Product Types and Applications
2.7 Global Key Manufacturers of circRNA-LNP Formulation, Date of Entry into the Industry
2.8 Global circRNA-LNP Formulation Market Competitive Situation and Trends
2.8.1 Global circRNA-LNP Formulation Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global circRNA-LNP Formulation Players Market Share by Revenue
2.8.3 Global circRNA-LNP Formulation Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global circRNA-LNP Formulation Market Scenario by Region
3.1 Global circRNA-LNP Formulation Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global circRNA-LNP Formulation Sales by Region: 2021–2032
3.2.1 Global circRNA-LNP Formulation Sales by Region: 2021–2026
3.2.2 Global circRNA-LNP Formulation Sales by Region: 2027–2032
3.3 Global circRNA-LNP Formulation Revenue by Region: 2021–2032
3.3.1 Global circRNA-LNP Formulation Revenue by Region: 2021–2026
3.3.2 Global circRNA-LNP Formulation Revenue by Region: 2027–2032
3.4 North America circRNA-LNP Formulation Market Facts & Figures by Country
3.4.1 North America circRNA-LNP Formulation Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America circRNA-LNP Formulation Sales by Country (2021–2032)
3.4.3 North America circRNA-LNP Formulation Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe circRNA-LNP Formulation Market Facts & Figures by Country
3.5.1 Europe circRNA-LNP Formulation Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe circRNA-LNP Formulation Sales by Country (2021–2032)
3.5.3 Europe circRNA-LNP Formulation Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific circRNA-LNP Formulation Market Facts & Figures by Region
3.6.1 Asia Pacific circRNA-LNP Formulation Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific circRNA-LNP Formulation Sales by Region (2021–2032)
3.6.3 Asia Pacific circRNA-LNP Formulation Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America circRNA-LNP Formulation Market Facts & Figures by Country
3.7.1 Latin America circRNA-LNP Formulation Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America circRNA-LNP Formulation Sales by Country (2021–2032)
3.7.3 Latin America circRNA-LNP Formulation Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa circRNA-LNP Formulation Market Facts & Figures by Country
3.8.1 Middle East and Africa circRNA-LNP Formulation Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa circRNA-LNP Formulation Sales by Country (2021–2032)
3.8.3 Middle East and Africa circRNA-LNP Formulation Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global circRNA-LNP Formulation Sales by Type (2021–2032)
4.1.1 Global circRNA-LNP Formulation Sales by Type (2021–2026)
4.1.2 Global circRNA-LNP Formulation Sales by Type (2027–2032)
4.1.3 Global circRNA-LNP Formulation Sales Market Share by Type (2021–2032)
4.2 Global circRNA-LNP Formulation Revenue by Type (2021–2032)
4.2.1 Global circRNA-LNP Formulation Revenue by Type (2021–2026)
4.2.2 Global circRNA-LNP Formulation Revenue by Type (2027–2032)
4.2.3 Global circRNA-LNP Formulation Revenue Market Share by Type (2021–2032)
4.3 Global circRNA-LNP Formulation Price by Type (2021–2032)
5 Segment by Application
5.1 Global circRNA-LNP Formulation Sales by Application (2021–2032)
5.1.1 Global circRNA-LNP Formulation Sales by Application (2021–2026)
5.1.2 Global circRNA-LNP Formulation Sales by Application (2027–2032)
5.1.3 Global circRNA-LNP Formulation Sales Market Share by Application (2021–2032)
5.2 Global circRNA-LNP Formulation Revenue by Application (2021–2032)
5.2.1 Global circRNA-LNP Formulation Revenue by Application (2021–2026)
5.2.2 Global circRNA-LNP Formulation Revenue by Application (2027–2032)
5.2.3 Global circRNA-LNP Formulation Revenue Market Share by Application (2021–2032)
5.3 Global circRNA-LNP Formulation Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Orna Therapeutics
6.1.1 Orna Therapeutics Company Information
6.1.2 Orna Therapeutics Description and Business Overview
6.1.3 Orna Therapeutics circRNA-LNP Formulation Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Orna Therapeutics circRNA-LNP Formulation Product Portfolio
6.1.5 Orna Therapeutics Recent Developments/Updates
6.2 GenScript
6.2.1 GenScript Company Information
6.2.2 GenScript Description and Business Overview
6.2.3 GenScript circRNA-LNP Formulation Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 GenScript circRNA-LNP Formulation Product Portfolio
6.2.5 GenScript Recent Developments/Updates
6.3 Creative Biogene
6.3.1 Creative Biogene Company Information
6.3.2 Creative Biogene Description and Business Overview
6.3.3 Creative Biogene circRNA-LNP Formulation Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Creative Biogene circRNA-LNP Formulation Product Portfolio
6.3.5 Creative Biogene Recent Developments/Updates
6.4 Catalent
6.4.1 Catalent Company Information
6.4.2 Catalent Description and Business Overview
6.4.3 Catalent circRNA-LNP Formulation Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Catalent circRNA-LNP Formulation Product Portfolio
6.4.5 Catalent Recent Developments/Updates
6.5 Creative Biolabs
6.5.1 Creative Biolabs Company Information
6.5.2 Creative Biolabs Description and Business Overview
6.5.3 Creative Biolabs circRNA-LNP Formulation Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Creative Biolabs circRNA-LNP Formulation Product Portfolio
6.5.5 Creative Biolabs Recent Developments/Updates
6.6 VectorBuilder
6.6.1 VectorBuilder Company Information
6.6.2 VectorBuilder Description and Business Overview
6.6.3 VectorBuilder circRNA-LNP Formulation Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 VectorBuilder circRNA-LNP Formulation Product Portfolio
6.6.5 VectorBuilder Recent Developments/Updates
6.7 Guangzhou Geneseed Biotech. Co., Ltd.
6.7.1 Guangzhou Geneseed Biotech. Co., Ltd. Company Information
6.7.2 Guangzhou Geneseed Biotech. Co., Ltd. Description and Business Overview
6.7.3 Guangzhou Geneseed Biotech. Co., Ltd. circRNA-LNP Formulation Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Guangzhou Geneseed Biotech. Co., Ltd. circRNA-LNP Formulation Product Portfolio
6.7.5 Guangzhou Geneseed Biotech. Co., Ltd. Recent Developments/Updates
6.8 Porton Pharma Solutions, Ltd
6.8.1 Porton Pharma Solutions, Ltd Company Information
6.8.2 Porton Pharma Solutions, Ltd Description and Business Overview
6.8.3 Porton Pharma Solutions, Ltd circRNA-LNP Formulation Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Porton Pharma Solutions, Ltd circRNA-LNP Formulation Product Portfolio
6.8.5 Porton Pharma Solutions, Ltd Recent Developments/Updates
6.9 Recipharm AB
6.9.1 Recipharm AB Company Information
6.9.2 Recipharm AB Description and Business Overview
6.9.3 Recipharm AB circRNA-LNP Formulation Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Recipharm AB circRNA-LNP Formulation Product Portfolio
6.9.5 Recipharm AB Recent Developments/Updates
6.10 Precigenome LLC
6.10.1 Precigenome LLC Company Information
6.10.2 Precigenome LLC Description and Business Overview
6.10.3 Precigenome LLC circRNA-LNP Formulation Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Precigenome LLC circRNA-LNP Formulation Product Portfolio
6.10.5 Precigenome LLC Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 circRNA-LNP Formulation Industry Chain Analysis
7.2 circRNA-LNP Formulation Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 circRNA-LNP Formulation Production Mode & Process Analysis
7.4 circRNA-LNP Formulation Sales and Marketing
7.4.1 circRNA-LNP Formulation Sales Channels
7.4.2 circRNA-LNP Formulation Distributors
7.5 circRNA-LNP Formulation Customer Analysis
8 circRNA-LNP Formulation Market Dynamics
8.1 circRNA-LNP Formulation Industry Trends
8.2 circRNA-LNP Formulation Market Drivers
8.3 circRNA-LNP Formulation Market Challenges
8.4 circRNA-LNP Formulation Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global circRNA-LNP Formulation Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global circRNA-LNP Formulation Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global circRNA-LNP Formulation Market Competitive Situation by Manufacturers in 2025
Table 4. Global circRNA-LNP Formulation Sales (Kg) of Key Manufacturers (2021–2026)
Table 5. Global circRNA-LNP Formulation Sales Market Share by Manufacturers (2021–2026)
Table 6. Global circRNA-LNP Formulation Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global circRNA-LNP Formulation Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market circRNA-LNP Formulation Average Price (US$/g) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of circRNA-LNP Formulation, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of circRNA-LNP Formulation, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of circRNA-LNP Formulation, Product Types and Applications
Table 12. Global Key Manufacturers of circRNA-LNP Formulation, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global circRNA-LNP Formulation Companies by Tier (Tier 1, Tier 2, Tier 3), based on circRNA-LNP Formulation Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global circRNA-LNP Formulation Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global circRNA-LNP Formulation Sales by Region (Kg), 2021–2026
Table 18. Global circRNA-LNP Formulation Sales Market Share by Region (2021–2026)
Table 19. Global circRNA-LNP Formulation Sales by Region (Kg), 2027–2032
Table 20. Global circRNA-LNP Formulation Sales Market Share by Region (2027–2032)
Table 21. Global circRNA-LNP Formulation Revenue by Region (US$ Million), 2021–2026
Table 22. Global circRNA-LNP Formulation Revenue Market Share by Region (2021–2026)
Table 23. Global circRNA-LNP Formulation Revenue by Region (US$ Million), 2027–2032
Table 24. Global circRNA-LNP Formulation Revenue Market Share by Region (2027–2032)
Table 25. North America circRNA-LNP Formulation Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America circRNA-LNP Formulation Sales by Country (Kg), 2021–2026
Table 27. North America circRNA-LNP Formulation Sales by Country (Kg), 2027–2032
Table 28. North America circRNA-LNP Formulation Revenue by Country (US$ Million), 2021–2026
Table 29. North America circRNA-LNP Formulation Revenue by Country (US$ Million), 2027–2032
Table 30. Europe circRNA-LNP Formulation Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe circRNA-LNP Formulation Sales by Country (Kg), 2021–2026
Table 32. Europe circRNA-LNP Formulation Sales by Country (Kg), 2027–2032
Table 33. Europe circRNA-LNP Formulation Revenue by Country (US$ Million), 2021–2026
Table 34. Europe circRNA-LNP Formulation Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific circRNA-LNP Formulation Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific circRNA-LNP Formulation Sales by Region (Kg), 2021–2026
Table 37. Asia Pacific circRNA-LNP Formulation Sales by Region (Kg), 2027–2032
Table 38. Asia Pacific circRNA-LNP Formulation Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific circRNA-LNP Formulation Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America circRNA-LNP Formulation Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America circRNA-LNP Formulation Sales by Country (Kg), 2021–2026
Table 42. Latin America circRNA-LNP Formulation Sales by Country (Kg), 2027–2032
Table 43. Latin America circRNA-LNP Formulation Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America circRNA-LNP Formulation Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa circRNA-LNP Formulation Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa circRNA-LNP Formulation Sales by Country (Kg), 2021–2026
Table 47. Middle East and Africa circRNA-LNP Formulation Sales by Country (Kg), 2027–2032
Table 48. Middle East and Africa circRNA-LNP Formulation Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa circRNA-LNP Formulation Revenue by Country (US$ Million), 2027–2032
Table 50. Global circRNA-LNP Formulation Sales (Kg) by Type (2021–2026)
Table 51. Global circRNA-LNP Formulation Sales (Kg) by Type (2027–2032)
Table 52. Global circRNA-LNP Formulation Sales Market Share by Type (2021–2026)
Table 53. Global circRNA-LNP Formulation Sales Market Share by Type (2027–2032)
Table 54. Global circRNA-LNP Formulation Revenue (US$ Million) by Type (2021–2026)
Table 55. Global circRNA-LNP Formulation Revenue (US$ Million) by Type (2027–2032)
Table 56. Global circRNA-LNP Formulation Revenue Market Share by Type (2021–2026)
Table 57. Global circRNA-LNP Formulation Revenue Market Share by Type (2027–2032)
Table 58. Global circRNA-LNP Formulation Price (US$/g) by Type (2021–2026)
Table 59. Global circRNA-LNP Formulation Price (US$/g) by Type (2027–2032)
Table 60. Global circRNA-LNP Formulation Sales (Kg) by Application (2021–2026)
Table 61. Global circRNA-LNP Formulation Sales (Kg) by Application (2027–2032)
Table 62. Global circRNA-LNP Formulation Sales Market Share by Application (2021–2026)
Table 63. Global circRNA-LNP Formulation Sales Market Share by Application (2027–2032)
Table 64. Global circRNA-LNP Formulation Revenue (US$ Million) by Application (2021–2026)
Table 65. Global circRNA-LNP Formulation Revenue (US$ Million) by Application (2027–2032)
Table 66. Global circRNA-LNP Formulation Revenue Market Share by Application (2021–2026)
Table 67. Global circRNA-LNP Formulation Revenue Market Share by Application (2027–2032)
Table 68. Global circRNA-LNP Formulation Price (US$/g) by Application (2021–2026)
Table 69. Global circRNA-LNP Formulation Price (US$/g) by Application (2027–2032)
Table 70. Orna Therapeutics Company Information
Table 71. Orna Therapeutics Description and Business Overview
Table 72. Orna Therapeutics circRNA-LNP Formulation Sales (Kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 73. Orna Therapeutics circRNA-LNP Formulation Product
Table 74. Orna Therapeutics Recent Developments/Updates
Table 75. GenScript Company Information
Table 76. GenScript Description and Business Overview
Table 77. GenScript circRNA-LNP Formulation Sales (Kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 78. GenScript circRNA-LNP Formulation Product
Table 79. GenScript Recent Developments/Updates
Table 80. Creative Biogene Company Information
Table 81. Creative Biogene Description and Business Overview
Table 82. Creative Biogene circRNA-LNP Formulation Sales (Kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 83. Creative Biogene circRNA-LNP Formulation Product
Table 84. Creative Biogene Recent Developments/Updates
Table 85. Catalent Company Information
Table 86. Catalent Description and Business Overview
Table 87. Catalent circRNA-LNP Formulation Sales (Kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 88. Catalent circRNA-LNP Formulation Product
Table 89. Catalent Recent Developments/Updates
Table 90. Creative Biolabs Company Information
Table 91. Creative Biolabs Description and Business Overview
Table 92. Creative Biolabs circRNA-LNP Formulation Sales (Kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 93. Creative Biolabs circRNA-LNP Formulation Product
Table 94. Creative Biolabs Recent Developments/Updates
Table 95. VectorBuilder Company Information
Table 96. VectorBuilder Description and Business Overview
Table 97. VectorBuilder circRNA-LNP Formulation Sales (Kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 98. VectorBuilder circRNA-LNP Formulation Product
Table 99. VectorBuilder Recent Developments/Updates
Table 100. Guangzhou Geneseed Biotech. Co., Ltd. Company Information
Table 101. Guangzhou Geneseed Biotech. Co., Ltd. Description and Business Overview
Table 102. Guangzhou Geneseed Biotech. Co., Ltd. circRNA-LNP Formulation Sales (Kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 103. Guangzhou Geneseed Biotech. Co., Ltd. circRNA-LNP Formulation Product
Table 104. Guangzhou Geneseed Biotech. Co., Ltd. Recent Developments/Updates
Table 105. Porton Pharma Solutions, Ltd Company Information
Table 106. Porton Pharma Solutions, Ltd Description and Business Overview
Table 107. Porton Pharma Solutions, Ltd circRNA-LNP Formulation Sales (Kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 108. Porton Pharma Solutions, Ltd circRNA-LNP Formulation Product
Table 109. Porton Pharma Solutions, Ltd Recent Developments/Updates
Table 110. Recipharm AB Company Information
Table 111. Recipharm AB Description and Business Overview
Table 112. Recipharm AB circRNA-LNP Formulation Sales (Kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 113. Recipharm AB circRNA-LNP Formulation Product
Table 114. Recipharm AB Recent Developments/Updates
Table 115. Precigenome LLC Company Information
Table 116. Precigenome LLC Description and Business Overview
Table 117. Precigenome LLC circRNA-LNP Formulation Sales (Kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 118. Precigenome LLC circRNA-LNP Formulation Product
Table 119. Precigenome LLC Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. circRNA-LNP Formulation Distributors List
Table 123. circRNA-LNP Formulation Customers List
Table 124. circRNA-LNP Formulation Market Trends
Table 125. circRNA-LNP Formulation Market Drivers
Table 126. circRNA-LNP Formulation Market Challenges
Table 127. circRNA-LNP Formulation Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
Table 131. Authors List of This Report
List of Figures
Figure 1. Product Picture of circRNA-LNP Formulation
Figure 2. Global circRNA-LNP Formulation Market Value by Type (US$ Million), 2021–2032
Figure 3. Global circRNA-LNP Formulation Market Share by Type: 2025 & 2032
Figure 4. Premade Product Picture
Figure 5. Customized Product Picture
Figure 6. Global circRNA-LNP Formulation Market Value by Application (US$ Million), 2021–2032
Figure 7. Global circRNA-LNP Formulation Market Share by Application: 2025 & 2032
Figure 8. Scientific Research
Figure 9. Pharmaceuticals
Figure 10. Global circRNA-LNP Formulation Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 11. Global circRNA-LNP Formulation Market Size (US$ Million), 2021–2032
Figure 12. Global circRNA-LNP Formulation Sales (Kg), 2021–2032
Figure 13. Global circRNA-LNP Formulation Average Price (US$/g), 2021–2032
Figure 14. circRNA-LNP Formulation Report Years Considered
Figure 15. circRNA-LNP Formulation Sales Share by Manufacturers in 2025
Figure 16. Global circRNA-LNP Formulation Revenue Share by Manufacturers in 2025
Figure 17. Top 5 and Top 10 Global circRNA-LNP Formulation Players: Market Share by Revenue in circRNA-LNP Formulation in 2025
Figure 18. circRNA-LNP Formulation Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 19. Global circRNA-LNP Formulation Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 20. North America circRNA-LNP Formulation Sales Market Share by Country (2021–2032)
Figure 21. North America circRNA-LNP Formulation Revenue Market Share by Country (2021–2032)
Figure 22. United States circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 23. Canada circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Europe circRNA-LNP Formulation Sales Market Share by Country (2021–2032)
Figure 25. Europe circRNA-LNP Formulation Revenue Market Share by Country (2021–2032)
Figure 26. Germany circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. France circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. U.K. circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Italy circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Russia circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Asia Pacific circRNA-LNP Formulation Sales Market Share by Region (2021–2032)
Figure 32. Asia Pacific circRNA-LNP Formulation Revenue Market Share by Region (2021–2032)
Figure 33. China circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Japan circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. South Korea circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. India circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Australia circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. China Taiwan circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Southeast Asia circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Latin America circRNA-LNP Formulation Sales Market Share by Country (2021–2032)
Figure 41. Latin America circRNA-LNP Formulation Revenue Market Share by Country (2021–2032)
Figure 42. Mexico circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Brazil circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Argentina circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Colombia circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Middle East and Africa circRNA-LNP Formulation Sales Market Share by Country (2021–2032)
Figure 47. Middle East and Africa circRNA-LNP Formulation Revenue Market Share by Country (2021–2032)
Figure 48. Turkey circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Saudi Arabia circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. UAE circRNA-LNP Formulation Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Global Sales Market Share of circRNA-LNP Formulation by Type (2021–2032)
Figure 52. Global Revenue Market Share of circRNA-LNP Formulation by Type (2021–2032)
Figure 53. Global circRNA-LNP Formulation Price (US$/g) by Type (2021–2032)
Figure 54. Global Sales Market Share of circRNA-LNP Formulation by Application (2021–2032)
Figure 55. Global Revenue Market Share of circRNA-LNP Formulation by Application (2021–2032)
Figure 56. Global circRNA-LNP Formulation Price (US$/g) by Application (2021–2032)
Figure 57. circRNA-LNP Formulation Value Chain
Figure 58. Channels of Distribution (Direct Vs Distribution)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
